Myositis facilitates preclinical accumulation of pathological prion protein in muscle by Melanie Neumann et al.
Neumann et al. Acta Neuropathologica Communications 2013, 1:78
http://www.actaneurocomms.org/content/1/1/78RESEARCH Open AccessMyositis facilitates preclinical accumulation of
pathological prion protein in muscle
Melanie Neumann1, Susanne Krasemann1, Katharina Schröck1, Karin Steinbach2 and Markus Glatzel1*Abstract
Background: In human and animal prion diseases, pathological prion protein, PrPSc, as well as prion infectivity is
mainly found in the central nervous system, but also in lymphoid organs and muscle. Pathophysiology of prion
colonization of lymphoid organs has been studied intensively, yet how myositis influences prion accumulation in
muscle is unknown.
Result: We have investigated the influence of myositis on PrPSc accumulation and prion infectivity in two distinct
mouse models of experimental autoimmune myositis. Furthermore, we have addressed the relevance of PrPC
expression in the lymphoreticular system in myositis by generating bone marrow chimeras.
Here we show that myositis positively influences muscular PrPSc accumulation at preclinical time points and that
PrPC-expression in the lymphoid system is critical for this. In muscle, PrPSc and prion infectivity are uncoupled with
detectable PrPSc but no prion infectivity at preclinical time points. Muscle has an intrinsically high ability to clear
PrPSc once myositis has ceased, possibly involving autophagy.
Conclusion: Our findings provide new insights into the pathophysiology of prion colonization in muscle pointing
out that myositis leads to enhanced prion colonization of muscle in subclinical prion disease.Background
Prion diseases are characterized by the accumulation of
misfolded prion protein (PrPSc), a posttranslationally modi-
fied form of the host-encoded prion protein (PrPC) [1]. Ac-
cumulation of PrPSc correlates with neurodegeneration,
and PrPSc represents an essential part of the infectious
agent causing prion disease [2-4]. Prion diseases occur in
animals as well as in humans and are transmissible within
and more rarely between mammalian species. Prion dis-
eases in animals include scrapie in sheep and goat [5],
chronic wasting disease in elk and deer [6], and bovine
spongiform encephalopathy in cattle [7]. Among the hu-
man prion diseases, three distinct etiologies are defined:
they either arise sporadically as in sporadic Creutzfeldt-
Jakob disease (sCJD), as autosomal dominantly inherited
diseases as in genetic Creutzfeldt-Jakob disease (gCJD) or
as acquired conditions in iatrogenic or variant Creutzfeldt-
Jakob disease (iCJD, vCJD) [8,9].* Correspondence: m.glatzel@uke.de
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stated.In prion diseases, accumulation of PrPSc and prion in-
fectivity is not confined to the nervous system. PrPSc
and prion infectivity are inevitably detectable in the
lymphoreticular system (LRS) or in the skeletal muscle
of terminally diseased individuals or animals [10-14]. In
the subclinical phase of disease, the situation differs.
Here PrPSc and prion infectivity are readily detectable in
the LRS in the majority of instances, whereas prion ac-
cumulation in muscle occurs to a lesser extent both
quantitatively and qualitatively [15-18].
Our knowledge on the pathophysiology of PrPSc accu-
mulation between LRS and muscle differs as well. For
prion colonization of the LRS, the molecular events have
been worked out in great detail. Here, follicular dendritic
cells (FDCs) residing in germinal centers of lymphoid
follicles accumulate PrPSc before prions find their way to
the central nervous system via peripheral nerves [19-21].
PrPC expression in muscle has been studied and it
could be shown that myocytes as well as muscle macro-
phages express PrPC [22] and that the expression in
muscle is highly regulated and fibre-type specific [23].
Overexpression of PrPC in muscle leads to a myopathy
and a wide range of myopathies are characterized byral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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less is known regarding molecular determinants of PrPSc
accumulation. PrPSc accumulation is muscle-type spe-
cific with hind limbs showing higher PrPSc content than
fore limb muscles [28]. Thus, the molecular mechanisms
underlying accumulation of PrPSc and prion infectivity
in skeletal muscle are poorly understood. Case studies
from patients with myositis and prion disease suggest
that inflammation may promote PrPSc accumulation
[29]. In fact, recent data indicate that ectopic follicular
inflammation is able to support prion accumulation even
in non-lymphoid tissue [30]. On the other hand, periph-
eral nerves or muscle spindles or myocytes, have been
shown to accumulate PrPSc even in the absence of in-
flammation [13,15,31].
Here, we show that PrPSc accumulation in skeletal
muscle of mice was enhanced upon induction of experi-
mental autoimmune myositis (EAM) in early subclinical
prion disease. Our data suggest that accumulation of
PrPSc correlates with elevated levels of PrPC at the peak
of myositis originating from infiltrating lymphocytes.
Once myositis ceased, PrPSc was rapidly cleared from
muscle most likely by autophagy which is upregulated in
muscle compared to spleen and brain. Accumulation of
PrPSc in inflamed muscle required presence of PrPC on
the LRS. Interestingly, titers of infectious prions as mea-
sured by bioassay were unchanged between the myositis
and the control cohort pointing to an uncoupling of




Five to six weeks old SJL/J and C57Bl/6 mice were pur-
chased from Charles River Laboratory (Sulzfeld,
Germany). Prion protein-deficient mice (Prnp0/0) [32]
were bred in house. Mice were sacrificed in groups of 4
animals at day 35, day 60, and day 90 after inoculation
with Rocky Mountain Laboratory (RML) prions or when
clinical signs of terminal prion disease (tail rigidity,
weight loss, ataxia, and roughened fur) occurred. All ani-
mal procedures were performed in accordance with the
institutional guidelines from the animal facility of the
University Medical Center Hamburg-Eppendorf.
Generation of bone marrow chimeras
C57Bl/6 mice were irradiated with a dosage of 8 Gy with
constant 1 Gy/min using a BIOBEAM 2000 Cs-137
chloride gamma irradiator (Eckert & Ziegler, Berlin,
Germany) one day prior to bone marrow reconstitution.
Bone marrow was harvested in serum-free media (D-
MEM) at 4°C from femur and tibia of the hind-legs of
Prnp0/0 and C57Bl/6 mice using a syringe with a 23 G
needle. The cell suspension was transferred to a 100 μmstrainer and the flow-through was centrifuged at 300 × g
for 10 min at 4°C. Cell pellets were solubilised in 1 ml of
erythrocytes-lysis-buffer containing 0.15 M NH4Cl,
10 mM KHCO3, and 0.1 mM Na2EDTA (pH = 7.2 to
7.4) and were then incubated for 5 min on ice. After-
wards cells were washed with PBS and transferred to a
40 μm strainer. The flow-through was directly used for
reconstitution. Each mouse was injected intravenously
with 300 μl of the cell suspension containing about 107
bone marrow cells in total and reconstitution efficiency
was assessed by FACS analysis (see below).
Induction of an experimental autoimmune myositis (EAM)
In order to induce an EAM, SJL/J mice were treated as
described before [33]. Briefly, purified myosin from
rabbit skeletal muscle (6.6 mg/ml; Sigma-Aldrich, Mun-
ich, Germany) was emulsified with an equal amount of
Complete Freund's adjuvant (CFA) (Difco Laboratories,
Detroit, USA) with 3.3 mg/ml Mycobacterium butyricum
(Difco Laboratories, Detroit, USA). Mice were anesthe-
tized using a CO2/O2 mixture and were then immunized
subcutaneously with 100 μl of the emulsion into four lo-
cations (total, 400 μl) on the back on days 0, 7, and 14.
On day 21 and 54 mice were either sacrificed for histo-
logical and FACS analysis or they were inoculated at day
21 with RML prions. In order to introduce an EAM in
C57Bl/6 mice, in addition animals were injected intra-
peritoneally with 0.5 μg Pertussis toxin in PBS at all time
points of immunizations.
Inoculations, determination of incubation time and prion
titers
At day 21 mice were anesthetized using an intraperito-
neal injection of ketamine (12 mg/ml) mixed with xyla-
zine (1.6 mg/ml) with a dosage of 100 μl solution per
10 g bodyweight. Afterwards mice were inoculated intra-
peritoneally with 100 μl PBS containing 6 logLD50 units
of RML scrapie strain. In order to determine the incuba-
tion time to onset of terminal prion disease, mice were
kept until the day of onset of terminal clinical signs of
prion disease (see above). Incubation time in days start-
ing from the day of scrapie administration until the day
of death was determined and plotted against the survival
probability in % in Kaplan-Meier survival curves using
SPSS statistic software.
Bioassays to determine titers of prion infectivity were
performed on 1% homogenates of either spleen or
muscle tissue. Spleens from one single animal per group
and muscle tissues from either 1 animal per group
(muscle control samples but day 90 and all chimeras), 2
animals per group (SJL/J mice day 35, day 60 and
terminal diseased) or 3 animals per group (SJLJ/ mice
day 90) were homogenized in 0.32 M sucrose using a
FastPrep FP120 homogenizer (Qbiogene, Cedex, France),
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500 × g. 30 μl of each supernatant were inoculated intra-
cerebrally into groups of 4 highly prion susceptible tga20
mice [34]. The relationship y = 11.45-0.088*x (y, log
LD50 per milliliter of homogenate; x, incubation time in
days to terminal disease) was used to calculate prion ti-
ters [35,36].
Immunohistochemistry
Muscle and brain tissues were either frozen in liquid
nitrogen-cooled 2-methyl-butan (Sigma Aldrich, Munich,
Germany) and cut into 8 μm sections with a cryostat
(CM1950, Leica, Wetzlar, Germany; see Figures 1a and 2),
or were fixed using 3.5% of formaldehyde solution buffered
according to Lillie for 15 hrs (see Figures 3c, 4c and 5b). If
appropriate, tissues were prion-inactivated using 98% for-
mic acid for 1 hr followed by 3.5% of formaldehyde solution
for at least 12 hrs. Tissues were processed to paraffin blocks
using an ASP300S dehydration machine (Leica, Wetzlar,
Germany) and an EG1160 tissue embedding system (Leica,
Wetzlar, Germany). Paraffin blocks were cut into 4 μm sec-
tions, which were stained with hematoxylin and eosin fol-
lowing standard laboratory procedures. Sections from
frozen tissue were also stained with Elastica-von-Giesson
standard staining solutions. For immunohistochemical
staining the Ventana Benchmark XT machine (Ventana,
Tuscon, Arizona, USA) was used. Briefly, deparaffinised
sections were boiled for 30 to 60 min in 10 mM citrate buf-
fer, pH 6.0, for antigen retrieval. Primary antibodies were
diluted in 5% goat serum (Dianova Immundiagnostic,
Hamburg, Germany), 45% Tris buffered saline pH 7.6
(TBS) and 0.1% Triton X-100 in antibody diluent solution
(Zytomed, Berlin, Germany). Sections were then incubated
with primary antibody for 1 hr (see also Table 1). Anti-
rabbit or anti-goat histofine Simple Stain MAX PO Univer-
sal immunoperoxidase polymer (Nichirei Biosciences,
Wedel, Germany) were used as secondary antibodies. De-
tection of secondary antibodies and counter staining was
performed with an ultraview universal DAB detection kit
from Ventana (Ventana, Tuscon, Arizona, USA) according
to the standard settings of the machine. The staining of
FDCs was performed according manufactures’ instructions.
All sections were cover-slipped using TissueTek® glove
mounting media (Sakura Finetek, Staufen, Germany), and
dried in an incubator at 60°C. Pictures were taken using a
light microscope (Axioskop 40, Zeiss, Jena, Germany or
Olympus BH-2, Hamburg, Germany) equipped with a
digital camera (AxioCam ICc3 Zeiss, Jena Germany).
Sodium phosphotungstic acid (NaPTA) precipitation
NaPTA precipitation was performed according to a pre-
viously, slightly modified method [14,37]. Briefly, 100 mg
of frozen tissue was thawed and put into 900 μl of dis-
sociation buffer containing 25 mM HEPES (pH 7.2),0.3 M sucrose and 53.6 μg Liberase Blendzyme 2 (Roche,
Penzberg, Germany). Samples were incubated for
30 min at 37°C with a ribolyzing step performed every
10 min, until completely homogenized. To each 500 μl
of 10% (w/v) tissue homogenates an equal volume of 4%
(w/v) sarkosyl-PBS was added, vortexed, and incubated
for 10 min at 37°C with constant agitation. 50 U/ml of
benzonase (Novagen, Darmstadt, Germany) and 1 mM
MgCl2 were added, and incubated at 37°C for 30 min
with vigorous agitation. Afterwards, 81.3 μl of a pre-
warmed (to 37°C) 4% (w/v) NaPTA/170 mM MgCl2 so-
lution (pH 7.4) was added, vortexed, and incubated with
vigorous agitation for 30 min at 37°C. Samples were then
centrifuged at 16,000 × g for 30 min, after which super-
natants were carefully removed and the remaining pel-
lets resuspended in 22.5 μl of 0.1% sarkosyl-PBS. For
detection of PrPSc only, samples were digested with pro-
teinase K (Invitrogen, Karlsruhe, Germany) for 60 min at
37°C with a final concentration of 20 μg/ml. Since PrPC
is proteinase K sensitive it is digested completely after
this treatment, whereas PrPSc is proteinase K resistant
and therefore is still detectable. Digestion was stopped
by adding CVL-sample buffer (1% (w/v) SDS; 25 mM
Tris/HCl, pH 7.4; 2,5% (v/v) β-mercaptoethanol; 1.5%
(w/v) sucrose; 0.02% (w/v) brome-phenol-blue) and boil-
ing for 10 min prior to Western blot analysis. As positive
control RML 5.0 standard inoculum brain homogenate
(RML) was spiked into uninfected tissue and digested as
described.
Western blots
Frozen tissues were thawed, homogenized and ~50 μg of
total protein were separated by SDS-PAGE on a 12% SDS-
PAGE gel, transferred to PVDF membranes (Biorad,
Munich, Germany) at 400 mA for 1 hr in a wet-blot cham-
ber (Biorad, Munich, Germany), and blocked for 1 hr at
room temperature in 5% (w/v) milk powder in PBS con-
taining 0.1% of Tween 20. Membranes were incubated
overnight at 4°C using anti-PrP antibody POM1 or for two
days using the anti-LC3 antibody, both in blocking buffer
(see also Table 1). After incubation for 1 hour at room
temperature with an HRP-conjugated anti-mouse second-
ary antibody (Promega GmbH, Mannheim, Germany,
1:5000 in blocking buffer), proteins were detected using
ECL femto reagent (Pierce, Rockford USA). Samples were
recorded and chemiluminescence signals were quantified
using a chemiluminescence reader (Biorad, Munich,
Germany). Detection of beta-actin (Sigma-Aldrich, Seelze,
Germany) served as an internal loading control.
FACS analysis of blood samples
Two drops of blood, drawn by submandibular puncture
were transferred into 5 ml of FACS buffer containing 2%
(v/v) FCS, 0.01 M EDTA (pH 8) and 0.1% (w/v) NaN3 in
Figure 1 Analysis of muscle tissue derived from myositis-induced SJL/J mice and untreated controls. a) H&E- as well as Elastica-von-
Giesson staining show a high number of infiltrating immune-cells at day 21 after the immunization with myosin, which is followed by a milder
invasion of inflammatory cells and necrosis of single muscle fiber at day 54. Immunohistochemical stainings of B-, T-cells and FDCs reveal that
most of the infiltrating cells are T-cells and that only very few B- cells or FDCs can be detected. (Scale bar is 50 μm). b) Western blot analysis of
PrPC of muscle, brain and spleen. Beta-actin (for muscle and brain) and coomassie-staining (for spleen) are shown as loading controls (molecular
weights indicated in kDa). c) Quantification of PrPC expression in muscle, brain and spleen. Values were adjusted to loading controls. Note that
there is a peak of PrPC expression at day 60 in muscle as well as in spleen in myositis-induced mice.
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Figure 2 Analysis of muscle derived from C57Bl/6 mice with
EAM and controls. H&E- as well as Elastica-von-Giesson staining
show a mild infiltration of immune-cells at day 21 after the
immunization with myosin. Immunohistochemical stainings of B-,
T-cells and FDCs reveal that most of the infiltrating cells are T-cells
and that only very few B-cells and no FDCs can be detected.
(Scale bar is 50 μm).
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1000 rpm supernatants were discharged and 100 μl of
primary antibody (biotinylated 6H4, Prionics, Planegg-
Martinsried, Germany) diluted 1:100 in FACS buffer was
added to the pellets and incubated at 4°C for 30 min.
Afterwards samples were washed and incubated with
fluorochrome-labelled streptavidin diluted 1:100 in
FACS buffer at 4°C for 30 min. After another washing
step samples were counterstained with an antibody
against T-cells (PE-anti-CD3 (2 μl per sample)) by incu-
bating at 4°C for 30 min. Following rigorous washing
steps, samples were resuspended in 0.5 ml of FACS buf-
fer and were analyzed using a LSRII FACS machine (BD
Bioscience, Heidelberg, Germany).
FACS analysis of muscle samples
Quadriceps femoris muscles of immunized mice were
dissected, minced and put into 5 ml of digestion bufferbefore incubation at 37°C for 30 min. Then, cooled (4°C)
samples were washed and passed through a 100 μm cell
strainer as well as through a 30 μm pre-separation filter
(Miltenyi Biotec, Bergisch Gladbach, Germany). The
flow-through was resuspended in 2.5 ml of a 30% Percoll
solution and underlayed with 2 ml of a 78% Percoll solu-
tion before centrifugation for 30 min at 2500 rpm. Cells
lying at the interface of the gradient were removed and
washed several times with FACS buffer. In order to
block Fc receptors before FACS analysis, pellets were in-
cubated for 10 min in 50 μl of FACS buffer containing
1 μl of Fc-block (eBioscience, Frankfurt, Germany). After
washing cells were stained for 1 hr using 10 μl of each of
the following antibodies: Gr1-FITC, NU1.1-PE, B220-
PECP-Cy5.5, CD11c-PECy7, CD11b-APC, CD45-APCCy7,
and CD3-PaBkuc. After washing cells were resuspended in
400 μl of FACS buffer and were analyzed using a LSRII
FACS machine (BD Bioscience, Heidelberg, Germany).
Statistical analysis
In all experiments, mean +/− SEM is reported. Statistical
comparisons among groups were determined using Stu-
dent’s t test.
Results
Induction of experimental autoimmune myositis (EAM)
in SJL/J mice
EAM was induced by subcutaneous injection of myosin
and CFA at days 0, 7 and 14. On day 21 and 54, quadriceps
femoris muscles of hind-legs were analyzed by FACS or
histology (Figure 6). As shown in Table 2, FACS revealed
T-cell dominated myositis (50.3 and 21.3% of all infiltrating
cells at day 21 and 54 were CD3-positive; 17.3 and 1.4% of
all infiltrating cells at day 21 and 54 were B220-positive) in
EAM mice when compared to controls (5.6% of all infiltrat-
ing cells were CD3-positive; 1.2% of all infiltrating cells
were B220-positive). Neutrophil granulocytes and other
lymphocytes were not changed between EAM and controls.
Up-regulation of T- and B-cells in EAM could be confirmed
histologically (Figure 1a), where we found prominent
lymphocytic infiltrates as early as day 21. Immunohisto-
chemical staining with antibodies against CD3 for T-cells,
B220 for B-cells and milk fat globule protein-epidermal
growth factor-8 (MFG-E8) for FDCs demonstrated high
numbers of T- and B-cells as well occasional MFG-E8-
positive cells in EAM when compared to control tissue. Less
pronounced infiltrates of T- and B-cells, but no MFG-E8-
positive cells could be detected at day 54 after
immunization. At both time points, morphological signs of
chronic myositis such as necrotic muscle fibers and fibrosis
were found in EAM but not in controls (Figure 1a). Inter-
estingly, myositis did not lead to a reduction in muscle
strength as demonstrated by hanging wire test (Additional
file 1: Figure S1). For further analysis, prion inoculations
Figure 3 Analysis of terminal diseased EAM / control mice. a) Kaplan-Meier curve showing no differences in survival probability in prion inoc-
ulated EAM-mice when compared to controls. b) Western blots of muscle, brain and spleen of terminal sick EAM / control mice. PrPSc loads are
variable without significant differences between groups. As positive control, brain homogenate from a terminally diseased wild type mouse is
loaded with and without PK-digestion. As negative control brain homogenate from a healthy wild type mouse is loaded with PK-digestion (mo-
lecular weights indicated in kDa). c) H&E as well as immunohistochemical staining for T-cell marker CD3 show signs of myositis in the muscle tis-
sue only in EAM mice but not controls. Nevertheless, in brain tissue in both cohorts a pronounced gliosis could be detected by H&E and
immunohistochemical staining for astrocyte marker GFAP (Scale bar is 100 μm and 20 μm for muscle and 200 μm and 20 μm for brain).
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first immunization). For reasons of clarity, day of RML/
sham (CD1 brain homogenate) inoculation was set to day
0, see Figure 6.
EAM leads to enhanced expression of PrPC in muscle
To investigate if EAM leads to an up-regulation of PrPC in
muscle, we analyzed muscle tissue for its PrPC content by
Western blotting and compared data to PrPC-levels in
spleen and brain. As shown in Figure 1, we could detect a
slight up-regulation of PrPC at day 60 after sham
immunization in muscle (Figure 1b,c; p = 0.1). In all othermuscle samples we could not find any changes in PrPC ex-
pression. As expected, brain showed high levels of PrPC
irrespective of EAM (Figure 1b,c). PrPC-levels in spleen
showed a considerable variation with a peak of PrPC
expression at day 60 after sham inoculation (Figure 1b,c,
p = 0.04).
EAM does not affect incubation time until onset of
terminal prion disease
Having established a reliable EAM-model, we analyzed if
EAM changed incubation time until onset of terminal
prion disease. For this, we induced EAM and inoculated
Figure 4 (See legend on next page.)
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Figure 4 Analysis of preclinical prion-inoculated EAM / control mice. a) NaPTA blots (muscle and brain) as well as regular Western blots
(spleen) show PrPSc load over time in EAM versus untreated mice. As positive controls for NaPTA blots RML is used as a spike in untreated tissue
homogenate and is either PK-digested or undigested. For blot of spleen brain homogenate from a terminally diseased wild type mouse is loaded
with and without PK- digestion. As a negative control, PK-digested normal tissue homogenate is used. Note that there are differences in PrPSc
loads in muscle at day 35 and 60 in EAM versus control mice. b) Quantifications of western blots of autophagy marker LC3 show elevated
amounts of LC3 II versus LC3 I in muscle versus spleen and brain of C57/Bl6 mice at day 0. (n = 4; control = brain homogenate of a cathepsin D
knockout mouse). c) H&E as well as immunohistochemical staining for CD3 show signs of myositis in the muscle tissue only in treated mice in
contrast to untreated controls. In brain tissue in both cohorts no gross pathological hallmarks of prion disease could be detected by H&E and
immunohistochemical staining for GFAP over time (scale bar is 200 μm and 20 μm for brain and 100 μm and 20 μm for muscle). d) Bioassays to
determine titers of prion infectivity reveal no differences between both prion-inoculated EAM and prion-inoculated control mice.
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sham. At identical time points, non-immunized SJL/J
mice were treated equally as control. There was no dif-
ference in incubation times until onset of terminal prion
disease between myosin-treated and non-treated mice
(Figure 3a). EAM mice came down with disease after
182 +/− 8 days and non-immunized mice after 177 +/−
3 days.
After a proteinase K digestion of tissue homogenates
we could detect presence of variable amounts of PrPSc
by Western blot analysis in muscle, brain and spleen
with no obvious differences in PrPSc loads and PrPSc
glycotypes between EAM and controls (Figure 3b,
Additional file 2: Figure S2).
In terminally sick mice, where the peak of active myo-
sitis has passed, morphological changes such as necrotic
muscle fibers or fibrosis, typical for post-myositic mus-
cles, were observed in EAM mice only (Figure 3c). In
brain, spongiform changes and astrogliosis, typical for
terminal prion disease were observed in both cohorts at
comparable extent (Figure 3c).
EAM leads to transient PrPSc accumulation in muscle in
subclinical prion disease
In order to analyze if EAM leads to changed kinetics of
PrPSc accumulation in muscle, we investigated PrPSc loads
by NaPTA-precipitation and Western blot analysis after
proteinase K digestion to detect PrPSc at 35, 60 and 90 days
post prion challenge (Figure 4a). At 35 as well as at 60 days
after prion inoculation, we detected prominent PrPSc accu-
mulation only in EAM mice, whereas we could not detect
significant levels of PrPSc in control mice. Interestingly, at
90 days after prion inoculation, none of the muscle samples
showed any PrPSc accumulation (Figure 4a), whereas at ter-
minal disease, PrPSc accumulation was equally strong in
EAM and control mice (Figure 3b). In brain and spleen
PrPSc accumulation was not influenced by EAM with high
PrPSc contents in spleen at all examined time points and
rising PrPSc contents in brain detectable from day 90 on-
wards (Figure 4a).
Since autophagy has been shown to clear PrPSc effect-
ively, we investigated if increased autophagy may help to
clear PrPSc in muscle. For this, we determined LC3levels in C57/Bl6 mice at day 0 in order to monitor if
autophagy is per se activated in muscle tissue versus
brain and spleen. As shown in Figure 4b, there was a
high up regulation of LC3 II, a marker for autophagy, in
muscle when compared to brain and spleen.
Histologically, signs of myositis could be observed in
muscle of EAM mice, but not in control animals at days
35 and 60. At day 90 only EAM mice showed necrotic
muscle fibers and fibrosis, both of which are routinely
observed as late signs of myositis (Figure 4c). In brain
no obvious pathological changes could be detected at
preclinical stages (Figure 4c).
Dissociation of PrPSc loads and prion infectivity titers in
muscle
PrPSc is thought to constitute an essential component of
prion infectivity. Nevertheless, presence of prion infect-
ivity does not strictly correlate with PK-resistant PrPSc
load and protease-sensitive PrPSc species harbor signifi-
cant amounts of prion infectivity [38]. Thus we assessed
prion titers of muscle and spleen by bioassay (Figure 4c).
Titers of infectious prions in muscle were under the de-
tection limit of the assay at early time points demon-
strating partial dissociation of PrPSc loads and prion
titer. At day 90, prion titers were around LD50 for both
cohorts with one EAM mouse (at day 129) and two con-
trol mice (at days 123 and 160) showing signs of prion
disease. However, at terminal disease stages high infect-
ivity titers (4.1 log LD50/ml of tissue homogenate for
EAM, 4.3 log LD50/ml of tissue homogenate for control)
could be measured in muscle. As expected, in spleen
high infectivity titers (3.8, 4.6, 4.8 and 5.2 log LD50/ml
tissue homogenate for EAM, and 4.5, 4.8, 4.7 and 4.9 log
LD50/ml tissue homogenate for controls) at days 30, 60,
90, and at terminal disease could be detected irrespective
of the presence of EAM.
PrPSc accumulation in muscle at early time points
requires a PrPC expressing lymphoreticular system
Next, we set out to examine which cell type in muscle
tissue is responsible for accumulation of PrPSc. Since we
could show that elevated PrPC levels in muscle occur dur-
ing peak of myositis (Figure 1c), cells of the hematopoietic
Figure 5 Analysis of preclinical prion-inoculated EAM / control mice with either Prnp0/0 or wt LRS. a) NaPTA blots of muscle and Western
blots of spleen for PrPSc over time in EAM versus control mice. As positive controls for NaPTA blots, RML is used as a spike (S) in untreated tissue
homogenate and is either PK-digested or undigested. As positive controls for spleen, brain homogenate from a terminally diseased wild type
mouse is loaded with and without PK-digestion. As a negative control, PK-digested normal tissue homogenate is used. Muscular PrPSc can only
be found in EAM mice with PrPC expressing LRS at day 35. At day 90, no PrPSc could be detected in both EAM and control mice. In spleen PrPSc
is detectable in all analyzed samples. b) Histological staining with H&E evidences signs of myositis in the muscle of both chimeric mice with EAM
but not controls. The staining for marker CD3 shows that most of the infiltrating cells are T-cells. Anti-PrPC staining could not be detected most
probably because its expression is under the detection limit of the method. In brain tissue in both cohorts no gross pathological hallmarks of
prion disease like spongiosis or gliosis could be detected by immunohistochemical staining for astrocyte marker GFAP. c) Bioassay to determine
prion infectivity titers reveal high infectivity titers for all analyzed spleen samples. In muscle, prion titers were under the detection limit of the
assay at day 35 irrespective of PrPC expression in the LRS. At day 90 borderline infectivity (attack rate of 25%) could be detected in mice with
PrPC-deficient LRS irrespective of myositis.
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vestigate the role of PrPC in the LRS we generated bone
marrow chimeras with a PrPC-expressing and PrPC-defi-
cient LRS. Since Prnp0/0 mice are kept on a C57Bl/6 back-
ground, and the majority of EAM models use a SJL/J
background [33], we first had to establish a protocol for the
induction of EAM in C57Bl/6 mice, thus allowing trans-
plantation of syngenic bone marrow.
EAM in C57Bl/6 mice was confirmed by FACS ana-
lysis of muscle at 21 days post induction showingincreased presence of T-cells (9.1% CD3-positive cells
for EAM; 4.4% CD3-positive cells for controls, see
Table 3). Upon histological analysis, we could observe T-
cell dominant perimysial infiltrates in EAM in C57Bl/6
mice (Figure 2). Interestingly, we could not observe
MFG-E8-positive FDCs and only a few B-cells.
To study PrPSc accumulation, we lethally irradiated
C57Bl/6 mice and reconstituted their bone marrow with
bone marrow of either Prnp0/0 or C57Bl/6 mice as a
control. The reconstitution efficiency was assessed by
Table 1 List of primary antibodies
Name Specificity Dilution Company
B220 B-cells 1:400 eBioscience
CD3 T-cells 1:100 Thermo Fisher Scientific
GFAP astrocytes 1:200 Dako
MFG-E8 follicular dendritic cells 1:50 BD Bioscience
LC3 autophagy 1:200 nanoTools
POM-1 PrPC and PrPSc 1:1000 kindly provided by A. Aguzzi
beta-Actin cytoskeleton 1:1000 Millipore
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lethal irradiation (Additional file 3: Figure S3). After-
wards, we induced EAM in 50% of the mice of both
groups (Prnp0/0 → C57Bl/6; C57Bl/6 → C57Bl/6) and
challenged them with either RML prions or mock at the
peak of myositis. Accumulation of PrPSc and infectious
prions was investigated by serially sacrificing mice at de-
fined time points (day 35 and 90) and detection of
muscular PrPSc loads by NaPTA-precipitation and
Western blots. Only in mice with a PrPC-expressing
hematopoietic compartment and EAM, we were able to
observe significant accumulation of PrPSc in muscle at
day 35 (Figure 5a). At day 90, no significant accumula-
tion of PrPSc could be detected in either group. In
spleen, PrPSc could be detected at day 35 and day 90 ir-
respective of the PrPC status of the hematopoietic com-
partment (Figure 5a).
In brain, as expected at this preclinical state of the dis-
ease, no spongiform changes or astrogliosis was seen
(Figure 5b). In muscle, signs of myositis could be ob-
served in both chimeric cohorts of mice after EAM but
not in control mice at day 35 and 90 (Figure 5b). Since
myositis is very mild in C57/Bl6 mouse lines compared
to SJL/J mice, immune cells infiltrate singular muscle fi-
bres (first, third and fourth row of pictures) or only theFigure 6 Schedule of the experiments. The upper timeline shows the da
displays the time after inoculation with RML or sham. Note that the day of
terminal disease.interstitial space (third row of pictures). Most infiltrating
cells are T-cells as shown with the immunohistochemical
staining of marker CD3. PrPC loads are not detectable in
muscle tissue by standard PrPC staining, since expres-
sion levels are under the detection limit of this method.
To study the correlation between PrPSc loads and ti-
ters of infectious prions, we assayed prion titers of
muscle and spleen by bioassay. As shown in Figure 5c,
no infectivity was detectable at day 35 whereas at day 90
individual mice came down with prion disease with an
attack rate below 50%, indicating that prion titers in
these tissues were at the detection limit of the assay. As
expected, in spleen high infectivity titers could be de-
tected at all given time points irrespective of PrPC ex-
pression in the LRS and myositis.
Discussion
Although, the central nervous system is the principal site of
prion accumulation and replication, and the only site where
prion-related tissue damage is seen, PrPSc and prion infect-
ivity can be found in peripheral compartments such as
spleen and muscle. Research focusing on mechanisms of
prion accumulation in the periphery has yielded important
insights into the temporal kinetics and prerequisites of
prion accumulation [39]. Presence of PrPSc and prion in-
fectivity in muscle has been highlighted by a number of re-
ports describing its presence in a wide range of instances
such as sporadic and variant CJD, BSE, CWD and Scrapie
[12,13,15,29,40,41]. PrPSc in muscle can be found preclini-
cally in prion-infected rodents and primates [31,42]. Both,
nerve fibres and myocytes have been shown to harbour
PrPSc within muscle at terminal disease stages [13,15,42],
yet in one patient with prion disease and myositis, PrPSc ac-
cumulation in muscle was surprisingly high [29]. In
summary, the pathophysiological events underlying accu-
mulation of PrPSc and prion infectivity in muscle specific-
ally also in myocytes is poorly understood and it is likelyys after immunization of the mice, whereas the lower timeline
inoculation is set to 0 again in order to calculate the exact days until
Table 2 FACS analysis of muscle homogenates from SJL/J
mice with EAE / control at day 21 and 54 after induction
of EAE
Infiltrating cells (in %) Control 21 days 54 days
T-cells 5.6 50.3 21.3
B-cells 1.2 17.3 1.4
Other lymphocytes 5.0 6.0 3.0
Neutrophile granulocytes 18.9 9.4 19.8
Values are the percentages of every immune cell regarding to the total
amount of infiltrating cells.
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terminal disease differ from those at early subclinical time
points. Detailed knowledge of the mechanisms controlling
prion colonization of muscle may help to explain the role
of muscle in neuroinvasion of prions from the periphery to
the brain [43,44]. Here, we studied the temporal kinetics of
PrPSc accumulation and prion titers in two murine EAM
models and generated bone marrow chimeras to investigate
the role of PrPC expression in the lymphoreticular system
in myositis.
As expected, in our EAM models, the peak of myositis
was reached 21 days following immunization [33]. At
this time point, we could observe significantly elevated
levels of PrPC in muscle by Western blot yet not by im-
munohistochemical methods. Increased expression of
PrPC has been linked to a number of diseases of the
muscle such as inclusion body myositis, dermato-, and
polymyositis [25,26]. Our data imply that this increase is
transient coinciding with inflammation. Although, pres-
ence of myositis did not influence disease kinetics with
regard to incubation times until terminal prion disease,
we could observe that presence of PrPSc at early subclin-
ical disease is augmented in EAM. Differences were
most drastic at days 35 and 60 following prion challenge.
Here, we could only detect very low amounts of PrPSc
by NaPTA-enhanced Western blotting in controls,
whereas mice with EAM showed high (at day 35) and
moderate (day 60) PrPSc loads in muscle. Surprisingly, at
a time point where the peak of myositis has passed (day
90), PrPSc was completely cleared from muscle. Al-
though, we did not investigate the mechanisms of PrPSc
clearance in detail, autophagy may contribute to this asTable 3 FACS analysis of muscle homogenates from
C57Bl/6 mice at day 21 after myosin infection or without
myositis as a control
Infiltrating cells (in %) Control 21 days
T-cells 4.4 9.1
B-cells 7.0 0.7
Other lymphocytes 7.1 2.1
Neutrophile granulocytes 17.8 37.1
Values are the percentages of every immune cell regarding to the total
amount of infiltrating cells.cell culture data [45] and our in vivo data show higher
rate of basal autophagy in muscle.
Preclinical PrPSc accumulation in muscle has been
demonstrated in a number of instances, yet we are not
aware of any study showing clearance of PrPSc from this
compartment after prion colonization has been estab-
lished [31,42,46].
We could observe an uncoupling of PrPSc and prion
infectivity in muscle at day 35 and 60, when significant
levels of PrPSc in EAM muscle occur in the absence of
prion infectivity. Similar findings have recently been re-
ported in the brain [47] and spleen [38]. Thus, our data
expand the range of tissues where PrPSc and prion in-
fectivity are not congruent and support the concept that
non-PrPSc species considerably contribute to prion in-
fectivity [47,48].
The fact that EAM does not influence incubation time
until onset of terminal prion disease is not surprising.
Even if absence of PrPSc accumulation or prion infectiv-
ity in lymphoid tissue dramatically slows down develop-
ment of prion disease, augmentation of prion replication
even in ectopic sites does not lead to shortening of incu-
bation time until onset of terminal prion disease [49,50].
At terminal prion disease, PrPSc and prion infectivity
could be observed irrespective of the presence of EAM.
This is in line with a wealth of papers detecting PrPSc in
muscle [12,13,29]. The fact that PrPSc is cleared from
muscle and reappears at terminal disease fits to a con-
cept where preclinical PrPSc results from lymphatic
spread whereas PrPSc in diseased animals is due to cen-
trifugal spread from the central nervous system [17,43].
It has been suggested that glycosylation patterns of
PrPSc differ between muscle and CNS [13]. We could
not observe such differences with muscular and brain-
derived PrPSc showing similar glycosylation patterns.
In the LRS, accumulation of PrPSc and prion infectivity
has been associated with FDC networks [20,51]. Since
myositis leads to diffuse and not follicular lymphoid in-
filtrates, we did not find FDC networks, but rather single
MFG-E8-positive cells in our EAM muscles. It is ques-
tionable if these represent bona fide FDCs or merely
MFG-E8-positive macrophages. In either case, accumu-
lation of PrPSc in muscle of EAM mice at early time
points occurs in the absence of FDC-networks.
Our experiments with bone marrow chimeras generating
mice with a PrPC-deficient LRS indicate that PrPC expres-
sion on cells of the LRS is decisive for early, EAM-
dependent accumulation of PrPSc in muscle. This sets early
inflammation-modulated PrPSc accumulation in muscle
apart from early PrPSc accumulation in spleen where PrPSc
accumulates irrespective of the PrPC status of the LRS [35].
In the spleen this property has been attributed to FDCs,
which are of non-hematopoietic origin and radio-resistant
[35]. Thus, it is plausible that in muscle, lack of FDC-
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is needed for PrPSc accumulation.
These data imply that myocytes are unlikely candidates
for accumulation of PrPSc in EAM at early time points.
A hypothesis that would accommodate current experi-
mental data, would conceive PrPSc accumulation in
muscle as a heterogeneous, disease stage-dependent
event. In early disease stages, PrPSc accumulation is
driven by cells of hematopoietic origin, whereas at late
disease stages, non-hematopoietic cells such as nerve fi-
bres or myocytes represent the main sites for PrPSc ac-
cumulation [13,15,17,18,31,52]. There have been major
concerns regarding biosaftey aspects of muscle biopsy in
subclinically prion-diseased patients [12,29]. Although
our data indicate that enhanced PrPSc-loads in muscle
may not be reflected by elevated prion titers it is not
possible to interpolate our data from mouse experiments
to the human situation and more research efforts are
needed to assess biosaftey aspects of muscle biopsy in
demented patients.
Conclusions
Our data show that: (i) myositis positively influences
PrPSc accumulation in homogenized muscle tissue at
preclinical time points and that a PrPC-expressing LRS
is a prerequisite for this, (ii) PrPSc and prion infectivity
are uncoupled in muscle with detectable PrPSc in the ab-
sence of prion infectivity at preclinical time points, (iii)
muscle, unlike the LRS, has an intrinsically high ability
to clear PrPSc once myositis has ceased, possibly involv-
ing autophagy.
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